QOL-26. Health-Related Quality of Life in Molecular Glioma Subtypes: A Pooled Analysis from 16 Randomized Trials
Year: 2025
Type: conference-abstract
Abstract: BACKGROUND Patients with traditional high-grade glioma (grade 3-4) generally report worse health-related quality of life (HRQoL) compared to patients with low-grade glioma (grade 1-2). However, HRQoL changes over time across different molecularly defined tumor types, and associations between HRQoL and tumor types are unclear. METHODS We examined HRQoL data from the CODAGLIO 2.0 database, comprising patients with glioma from 16 randomized controlled trials. HRQoL was measured using the EORTC QLQ-C30 and QLQ-BN20 questionnaires. We analyzed differences in mean HRQoL at baseline and 3-month follow-up across tumor types (glioblastoma IDH-wildtype, astrocytoma IDH-mutant, and oligodendroglioma IDH-mutant/1p19q codeleted) and used linear mixed models (LMMs) to assess factors independently associated with HRQoL outcomes. RESULTS We included 4,301 patients with baseline HRQoL data, of which 3,215 (75%) had 3-month follow-up assessments. In stratified analyses, at 3 months, physical, role, and cognitive functioning were statistically and clinically significantly worse in glioblastoma compared to astrocytoma and oligodendroglioma. In LMMs, patients with astrocytoma showed worse physical functioning (-2.78, 95% CI: -4.68 to -1.01), cognitive functioning (-3.63, -6.18 to -1.05), pain (2.74, 0.41-4.95), communication deficits (5.03, 2.44-7.66), and seizures (4.49, 2.55-6.72), and oligodendroglioma patients showed worse social functioning (-5.39, -10.57 to -0.11), communication deficits (7.40, 1.63-12.81), and seizures (8.61, 4.17-14.26), compared to glioblastoma. None of these associations reached the threshold for clinical relevance. WHO performance status (PS) was the only variable in multivariable analysis with both statistically and clinically significant associations in 5/8 HRQoL scales. CONCLUSION Patients with glioblastoma show statistically clinically significantly worse physical and role functioning compared to IDH-mutant glioma. However, after adjusting for other variables in LMMs, patients with glioblastoma show statistically but not clinically significantly better HRQoL on several scales than patients with IDH-mutant glioma. WHO PS should be considered a critical factor in clinical decision-making, given its clinically meaningful association with most HRQoL scales.
Source: Neuro-Oncology
Authors: Ogechukwu A Asogwa, Linda Dirven, Alba A Brandes, Luigi Lim, Annika Malmström, Brigitta G Baumert, Caroline Hertler, Christine Marosi, Claudia Panciroli, Clemens Seidel, Emilie Le Rhun, Florence Keime-Guibert, Francesca Martinelli, Jaap C Reijneveld, Kathy Oliver, Martin van den Bent, Matthijs van der Meulen, Mirjam Renovanz, Neil K Aaronson, Paul M Clement, Roger Stupp, Thierry Gorlia, Ulrich Herllinger, Wolfgang Wick, Michael Weller, Martin J B Taphoorn, Johan A F Koekkoek
Institutions: Leiden University Medical Center, Istituto delle Scienze Neurologiche di Bologna, European Organisation for Research and Treatment of Cancer, Linköping University, Kantonsspital Graubünden, University of Zurich, University Hospital Zurich, Medical University of Vienna, Institut Català d'Oncologia, IRCCS Ospedale San Raffaele, University Hospital Leipzig, Leipzig University, Amsterdam University Medical Centers, Erasmus MC Cancer Institute, Universitätsklinikum Tübingen, Hertie Institute for Clinical Brain Research, University of Tübingen, The Netherlands Cancer Institute, KU Leuven, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Bonn, University Hospital Bonn, German Cancer Research Center, Heidelberg University, University Hospital Heidelberg
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4416139870
Cites:
Cited by:
Related to: